Last reviewed 2026-05-27 · How we verify

Oxypertin (OXYPERTINE)

Phase 2 active Small molecule ✓ Verified May 2026

Oxypertin (generic name: OXYPERTINE) is a oxypertine drug. It is currently in Phase 2 development for Schizophrenia.

Oxypertine is thought to work by modulating neurotransmitter activity in the brain.

Oxypertin is a small molecule with the synonyms FORIT, INTEGRIN, INTEGRIN (FLAVONE), OXIPERTINA, OXIPERTINE, and OXYPERTINE.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	OXYPERTINE
Drug class	oxypertine
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Imagine your brain is a busy city with many different streets and intersections. Oxypertine helps to calm down some of the busy streets by adjusting the flow of chemical messengers, or neurotransmitters, that carry signals between different parts of the brain. This can help to reduce symptoms of schizophrenia, such as hallucinations and disorganized thinking.

Approved indications

Schizophrenia

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Oxypertin CI brief — competitive landscape report
Oxypertin updates RSS · CI watch RSS

Frequently asked questions about Oxypertin

What is Oxypertin?

Oxypertin (OXYPERTINE) is a oxypertine drug, indicated for Schizophrenia.

How does Oxypertin work?

Oxypertine is thought to work by modulating neurotransmitter activity in the brain.

What is Oxypertin used for?

Oxypertin is indicated for Schizophrenia.

What is the generic name of Oxypertin?

OXYPERTINE is the generic (nonproprietary) name of Oxypertin.

What drug class is Oxypertin in?

Oxypertin belongs to the oxypertine class. See all oxypertine drugs at /class/oxypertine.

What development phase is Oxypertin in?

Oxypertin is in Phase 2.

Drug class: All oxypertine drugs
Therapeutic area: All drugs in Neuroscience
Indication: Drugs for Schizophrenia

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing